Related Experiment Videos
Hyperthermic limb perfusion for malignant melanoma and soft tissue sarcoma
C Kettelhack1, T Kraus, T Hupp
1Department of Surgery, University of Heidelberg, FRG.
Summary
Hyperthermic limb perfusion effectively treats malignant melanoma and soft tissue sarcoma. This study shows high survival rates for early-stage melanoma and manageable complications for advanced cases.
Area of Science:
- Oncology
- Surgical Oncology
- Medical Technology
Background:
- Malignant melanoma and soft tissue sarcoma present significant treatment challenges.
- Hyperthermic limb perfusion (HLP) is a regional therapy approach.
- Evaluating HLP efficacy and safety is crucial for clinical decision-making.
Purpose of the Study:
- To assess the efficacy of hyperthermic limb perfusion for malignant melanoma and soft tissue sarcoma.
- To determine the survival rates and complication profiles associated with HLP.
Main Methods:
- Retrospective analysis of 113 hyperthermic limb perfusions in 102 patients from 1982-1989.
- Patients included those with malignant melanoma (n=93) and soft tissue sarcoma (n=9).
- Outcomes measured included survival rates and complication incidence.
Main Results:
- High-risk stage I melanoma patients (n=47) had an 89% 5-year survival rate.
- Recurrent/metastatic melanoma patients (n=46) had a projected 40% 5-year survival rate.
- Soft tissue sarcoma patients experienced low rates of recurrence and amputation; common side effects included erythema, edema, skin reactions, and nerve palsy.
Conclusions:
- Hyperthermic limb perfusion demonstrates efficacy in treating malignant melanoma, particularly high-risk stage I.
- HLP is a viable option for selected soft tissue sarcoma cases, including local recurrences.
- The procedure is associated with a low rate of major complications and mortality.